Global Gene Expression Profiling in PAI-1 Knockout Murine Heart and Kidney: Molecular Basis of Cardiac-Selective Fibrosis

Asish K. Ghosh*, Sheila B. Murphy, Raj Kishore, Douglas E. Vaughan*

Feinberg Cardiovascular Research Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America

Abstract

Fibrosis is defined as an abnormal matrix remodeling due to excessive synthesis and accumulation of extracellular matrix proteins in tissues during wound healing or in response to chemical, mechanical and immunological stresses. At present, there is no effective therapy for organ fibrosis. Previous studies demonstrated that aged plasminogen activator inhibitor-1 (PAI-1) knockout mice develop spontaneously cardiac-selective fibrosis without affecting any other organs. We hypothesized that differential expressions of profibrotic and antifibrotic genes in PAI-1 knockout hearts and unaffected organs lead to cardiac selective fibrosis. In order to address this prediction, we have used a genome-wide gene expression profiling of transcripts derived from aged PAI-1 knockout hearts and kidneys. The variations of global gene expression profiling were compared within four groups: wildtype heart vs. knockout heart; wildtype kidney vs. knockout kidney; knockout heart vs. knockout kidney and wildtype heart vs. wildtype kidney. Analysis of illumina-based microarray data revealed that several genes involved in different biological processes such as immune system processing, response to stress, cytokine signaling, cell proliferation, adhesion, migration, matrix organization and transcriptional regulation were affected in hearts and kidneys by the absence of PAI-1, a potent inhibitor of urokinase and tissue-type plasminogen activator. Importantly, the expressions of a number of genes, involved in profibrotic pathways including Ankrd1, Pi16, Egr1, Sca, Timp1, Timp2, Klf6, Lox1 and Klotho, were deregulated in PAI-1 knockout hearts compared to wildtype hearts and PAI-1 knockout kidneys. While the levels of Ankrd1, Pi16 and Timp1 proteins were elevated during EndMT, the level of Timp4 protein was decreased. To our knowledge, this is the first comprehensive report on the influence of PAI-1 on global gene expression profiling in the heart and kidney and its implication in fibrogenesis and several other biological processes. The significance of these observations in the light of heart-specific profibrotic signaling and fibrogenesis are discussed.

Introduction

In response to injury, the body’s defense system immediately responds leading to induction of inflammation which is an essential event during wound healing. Initially, vascular injury causes mononuclear cell infiltration/inflammation in affected organs. The infiltrating cells produce a wide variety of cytokines including the profibrotic cytokine TGF-β that activates fibroblast migration to the injury site. Activated fibroblasts undergo differentiation to myofibroblasts that synthesize collagen and other extracellular matrix proteins and play a pivotal role in wound healing [1–4]. However, unchecked wound healing leads to loss of tissue homeostasis due to excessive synthesis and deposition of collagens by activated myofibroblasts in the wound area, a pathological manifestation of organ fibrosis [1–6]. Fibrosis is an end-stage pathological manifestation of numerous injury related diseases where different deregulated biological processes such as inflammation, cellular migration, proliferation, senescence and cytokine signaling participate and contribute to disease progression [1,2,7,8]. At present, there is no effective therapy for organ fibrosis. In order to develop a novel therapeutic approach, it is important to identify the molecule(s) which ignite(s) the onset of fibrogenesis. Previous studies demonstrated that aged PAI-1 knockout mice develop cardiac-specific fibrosis without affecting any other organ [8–10] and thus provide an excellent animal model for identification of factor(s) that ignite(s) organ-specific fibrosis.

Plasminogen activator inhibitor-1 (PAI-1), a member of the serine protease inhibitor (serpin) gene superfamily, is the major physiologic inhibitor of serine proteases, urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA). The PAI-1 gene, codes for 48–50 kDa polypeptides with two well-characterized functional domains: vitronectin binding domain required for anchoring PAI-1 to extracellular matrix and reactive center loop (RCL) required for inhibition of u-PA and t-PA activities. PAI-1 is synthesized by a wide variety of cells including endothelial cells, adipocytes, cardiomyocytes, fibroblasts and macrophages. Active PAI-1 controls several biological processes
in a cell-type- and tissue-type-specific manner including cellular proliferation, migration, adhesion, apoptosis, senescence, blood coagulation via modulating the activities of cytokines and transcriptional regulators [5,11–13]. Through inhibition of uPA/ tPA, PAI-1 inhibits the plasminogen-to-plasmin conversion and plasmin-dependent matrix metalloproteinase (MMP) activation. Non-physiologic levels (both decreased and increased) of this secreted serine protease inhibitor are associated with a wide variety of human diseases such as obesity, insulin resistance, diabetes, cardiovascular diseases, abnormal bleeding, emphysema, thrombosis, atherosclerosis, cancer, impairment of wound healing and multi-organ fibrosis [5,14,15]. Numerous studies demonstrated that in injury-induced fibrotic tissues, the level of PAI-1 is significantly elevated and plays an important role in fibrogenesis via suppression of the proteolytic degradation of extracellular matrix proteins [5]. Furthermore, PAI-1 deficient mice are protected from bleomycin-induced lung fibrosis and unilateral ureteral obstruction (UUO)-induced renal fibrosis suggesting the positive role of PAI-1 in fibrogenesis [16,17]. Paradoxically, PAI-1 deficiency is associated with age-dependent spontaneous cardiac selective fibrosis and is characterized by the presence of inflammation, elevated levels of TGF-ß, constitutively activated Smads and Erk1/2 MAPK, increased number of fibroblast-like cells and excessive collagen accumulation in pericardial, perivascular and interstitial areas [8–10]. Furthermore, PAI-1-deficient endothelial cells are more susceptible to endothelial to mesenchymal transition (EndMT) and EndMT-derived myofibroblast-like cells may contribute to elevated collagen synthesis and cardiac fibrogenesis [reviewed in [5,8,18]]. However, the molecular basis of spontaneous cardiac-selective fibrosis in this murine model is an enigma.

As global PAI-1 knockout mice (the whole coding region and part of the promoter deleted) [19,20] develop age-dependent spontaneous fibrosis only in the hearts (8–10), we asked the most fundamental questions: why are the kidney and other organs not affected by fibrogenesis in PAI-1 knockout mice? Why does only the PAI-1 knockout heart develop fibrosis? In other words, what are the factors that ignite fibrogenesis in the heart? What is the status of those factors in PAI-1 knockout kidneys? We hypothesized that specific regulator(s) involved in initiation of fibrogenesis are differentially expressed in the PAI-1 knockout heart and kidney. In order to address this prediction, we examined the global gene expression profile in hearts and kidneys derived from aged wildtype and PAI-1 knockout mice using Illumina-based microarray analysis. We have identified several genes that are differentially expressed in PAI-1 knockout hearts and kidneys compared to wildtype controls. Importantly, we have identified a number of important regulators related to matrix remodeling and cardiac hypertrophy, which are upregulated in PAI-1 knockout hearts compared to wildtype hearts and PAI-1 knockout kidneys. The significance of these novel findings in the light of cardiac-specific fibrogenesis is discussed.

**Materials and Methods**

**Experimental Animals and Organ Collection**

PAI-1 knockout (PAI-1KO) and wild-type (WT) mice on a C57BL/6 background were purchased from Jackson laboratory (Bar Harbor, ME) and were maintained for 12–24 months. All mouse protocols were approved by the Animal Care and Use Committee of Northwestern University (Chicago, IL). The mice were sacrificed at the age of 12–24 months and heart, kidney, liver and lung were collected. Part of the heart, kidney, liver and lung was fixed in formalin and stored for histochemical analysis. The other half of the organ was snap frozen and stored at −80°C for RNA and biochemical analysis.

**Histology and Collagen Staining**

For histological studies, fixed hearts derived from wildtype and PAI-1 knockout mice (n = 3–5) were sectioned in the short axis along the mid ventricle. The fixed kidneys, livers and lungs were sectioned and processed for staining. The levels of collagen deposition in hearts and kidneys were determined by Mason's trichrome staining. Photographs were taken with an Olympus DP71 camera as described [8]. For quantification of fibrotic areas, Mason's trichrome stained sections (whole tissues or 5 fields/mice) were analyzed with Image-Pro-Plus 6.3 software (Media Cybernetics, Bethesda, MD).

**RNA Extraction from Hearts and Kidneys Derived from PAI-1 Knockout and Wildtype Mice**

Total RNA was extracted from hearts and kidneys derived from three PAI-1 knockout (12- month old) and three wild-type mice (12-month old) using RNeasy Fibrous Tissue Mini Kit (Qiagen, Valencia, CA) following the manufacturer's instructions. In short, heart and kidney tissues were homogenized in RLT buffer using Tissue Lyser. The tissue lysate was mixed with RNase-free water and proteinase K and incubated at 55°C for 10 min. The lysate was centrifuged and supernatant was mixed with ethanol and the mixture was loaded to RNeasy mini column and centrifuged. Buffer RW1 was added to the column and centrifuged. DNano in RDD buffer was added to the column and incubated for 15 min at 25°C. The RNeasy column was washed with RW1 buffer and RPE buffer. The total RNA was collected in a new centrifuge tube using 50 μl RNase-free water and centrifugation. The concentrations of total RNA in each heart tissue and kidney tissue were determined by spectrophotometric analysis. The quality of RNA (RNA Integrity, RIN) in all 12 samples (3 wildtype hearts; 3 PAI-1 KO hearts; 3 wildtype kidneys; and 3 PAI-1 KO kidneys) was checked using the bioanalyzer.

**First and Second cDNA Strand Synthesis: cRNA Synthesis**

For first strand synthesis, T7 oligo(dT) Primer, 10X First Strand Buffer, dNTP Mix, and RNase inhibitor were added in a RNA containing tube (20 μl) and incubated at 42°C for 2 h. To prepare the second strand, nuclease free water, 10X Second Strand buffer, dNTP Mix, DNA polymerase, and RNaseH (80 μl) were mixed. The master mix was transferred to each first strand synthesized sample and incubated at 16°C for 2 h. eDNA purification: 250 μl of eDNA binding buffer was added to each sample and mixed thoroughly before placing onto the middle of the filter Cartridge. The sample was centrifuged for 2 min and the flow-through was discarded. The eDNA filter cartridge was washed with wash buffer. The sample was centrifuged and flow-through was discarded. The cartridge was transferred to the cDNA elution tube and 10 μl of warm (33°C) nuclease free water was added. The sample was incubated at room temperature for 2 min and was centrifuged to collect the cDNA. A second aliquot of 10 μl preheated nuclease free water was applied and centrifuged for 2 min. The tubes were kept on ice for further processing.

**In vitro Transcription Reaction and cRNA Purification**

T7 10X Reaction Buffer, T7 Enzyme Mix, Biotin-NTP Mix (total volume 7.5 μl) were mixed and spun for a few seconds. 7.5 μl of the IVT mix was added to each purified cDNA sample
and mixed well. The sample was incubated at 37°C for 14 h. 350 μl of cRNA binding buffer followed by 250 μl of ethanol was added to each sample and mixed. The mixture was transferred to the cRNA filter cartridge and centrifuged for 2 min. The flow-through was discarded and 650 μl wash buffer was added to each cRNA filter cartridge and centrifuged. The filter cartridge was transferred to the fresh cRNA collection tubes and 40 μl warm nuclease free water was added. The filter was incubated at room temperature for 2 min and centrifuged. The quality of the sample was checked and the concentration of the cRNA was measured using the bioanalyzer.

Microarray Procedure: Illumina Gene Expression Analysis QC Report

Twelve samples were processed. All the samples met the Illumina standard quality control checks. Data quality checks were performed using Bioconductor Lumi package [21] for R statistical programming environment. The data processing also included a normalization procedure utilizing quantile normalization method [22] to reduce the obscuring variation between microarrays, which was introduced during the processes of sample preparation, manufacture, fluorescence labeling, hybridization and/or scanning. Hierarchical clustering and Principal Component Analysis were performed on the normalized signal data to assess the sample relationship and variability. Multiple metrics were taken to assess the overall quality of the hybridization. The advantage of quantile normalization is that it preserves the rank order of genes and has computation efficiency. However, it is possible that quantile normalization may eliminate differentially expressed genes whose intensity values are small.

Relationship among and Variability of the Samples (Arrays)

Hierarchical clustering and multi-dimensional scaling analyses were performed to assess the relationship and variability of the samples. All the 4 groups were clearly separated from each other. The MvA plots showed that there was a large variation between certain groups, such as Group2 (KO/HT) vs Group4 (KO/KID) and Group1 (WT/HT) vs. Group3 (WT/KID), suggesting big changes in gene expression. The biological replicates were very consistent. The variation between other groups, eg. Group1 (WT/HT) vs Group2 (KO/HT) and Group3 (WT/KID) vs. Group4 (KO/KID) was very small. Based on the analyses above, the overall data quality for all the 12 samples was acceptable.

Data Filtering and Microarray Gene Expression Analysis Method

As most genes are expressed only under certain conditions, lots of genes have expression signals below the background. These are defined by Illumina as “absent”. Probes absent in all samples were filtered out, leaving 19780 probes corresponding to 11105 genes in the downstream analysis. Differential gene expression between the different conditions was assessed by a statistical linear model analysis using the bioconductor package limma, in which an empirical Bayes method was used to moderate the standard errors of the estimated log-fold changes of gene expression. This method results in more stable inference and improved power, especially for experiments with small numbers of microarrays [23,24]. The moderated t-statistic p-values derived from the limma analysis were further adjusted for multiple testing by Benjamini and Hochberg’s method to control false discovery rate (FDR). The lists of differentially expressed genes were obtained by the criteria of p-value < 0.05 and fold change cutoff 1.5 for WT/HT vs KO/HT and WT/KID vs KO/KID and criteria of FDR <10% and fold change cutoff 1.5 for WT/HT vs WT/KID and KO/HT vs. KO/KID, and visualized by volcano plots. The microarray data has been deposited to NCBI GEO with the access number GSE46920.

Quantitative qPCR of Genes for Validation: Procedure Real-Time Reverse-Transcription Polymerase Chain Reaction Analysis

The messenger RNA (mRNA) levels were quantified by complementary DNA synthesis (iScript cDNA Synthesis Kit, Bio-Rad, Hercules, CA) and quantitative polymerase chain reaction with SYBR Green SuperMix for iQ (Quanta Bioscience, Gaithersburg, MD). Levels of Ankrd1, Pi16, Egr1, Dbp and TIMP-1 were measured by quantitative PCR using gene specific primers and All-in-one qPCR kit (GeneCopeia, Rockville, MD).

Endothelial to Mesenchymal Transition (EndMT) Study and Western Blot Analysis

Mouse cardiac endothelial cells were cultured in 10% FBS containing EBM-2 media. The cells were cultured overnight at 2% FBS containing media and treated with TGF-β2 for 7 days. At the end of the incubation, cells were harvested and whole cell lysates were prepared. Equal amount of proteins were loaded on a 4–12% Tris-glycine gradient gel and processes for immunoblot analysis as described [8] using antibodies (1 μg/ml) against Ankrd1 (Novus Biologicals, Littleton, CO), Pi16 (R&D, Minneapolis, MN), Timp1 (Santa Cruz Biotech, Santa Cruz, CA), Timp4 (Millipore, Billerica, MA) and Actin (Abcam, Cambridge, MA).

Statistical Analysis

Data are presented as Mean ± SEM. The significance of differences between controls and experimental groups were estimated by t-test and a value of P<0.05 by Student t test was considered statistically significant. Statistical analyses were performed with GraphPad Prism 3.0 (GraphPad Software Inc, San Diego, CA).

Results

Pathological Manifestation of Fibrosis in Hearts and Kidneys Derived from 12-month and 24-month Old Wildtype and PAI-1 Knockout Mice

Previously, we reported that PAI-1 deficiency is associated with age-dependent cardiac fibrosis [8]. Hearts and kidneys explanted from aged PAI-1 knockout and wildtype mice were subjected to histological study. Levels of collagen were measured by Masson’s trichrome staining. Results revealed that while myocardial tissues derived from 12-month old PAI-1 knockout mice showed modest accumulation of collagen compared to age-matched wildtype controls (Wildtype 12 m 0.0057±0.0015 μg/mg tissue vs. PAI-1 knockout 12 m 0.0341±0.0248 μg/mg tissue; p = 0.09), myocardial tissues derived from 24-month old PAI-1 knockout mice showed significantly elevated levels of collagen accumulation compared to age- and sex-matched wildtype controls (Wildtype 24 m 0.0143±0.006 vs. PAI-1 knockout 24 m 0.1546±0.0144 μg/mg tissue; p = 0.0004) (Figure 2A–D). In contrast, collagen accumulation in kidneys derived from both 12-month and 24-month old PAI-1 knockout mice were insignificant and comparable with age- and sex-matched wildtype controls (Wildtype 12 m 0.00125±0.00029 vs. PAI-1 knockout 12 m 0.00125±0.00029 μg/mg tissue; p = 0.91) (Figure 2A–D).
0.00153 ± 0.00035; p = 0.55) (Wildtype 24 m 0.00248 ± 0.00052 vs. PAI-1 knockout 24 m 0.00177 ± 0.00033; p = 0.24) (Figure 2E–H) suggesting PAI-1 deficiency is associated with age-dependent cardiac-selective fibrosis. Results also revealed that PAI-1 deficiency is not associated with age-dependent fibrosis in liver (Wildtype 24 m 0.00203 ± 0.00051 vs. PAI-1 knockout 24 m 0.00125 ± 0.00017; p = 0.11) and lung (Wildtype 24 m 0.00209 ± 0.00054 vs. PAI-1 knockout 24 m 0.00196 ± 0.00054; p = 0.86) compared to age-matched wildtype controls (Figure S1). As the molecular events of fibrogenesis start earlier, before the pathological manifestation of fibrosis, we decided to study the global gene expression profiling in 12-month old PAI-1 knockout mice where pathological manifestation of fibrosis or accumulation of collagen is not significant. We anticipated that this would help us to identify the regulatory factors responsible for initiation of fibrogenesis in the heart.

Hierarchical Clustering of Gene Expression: Summary and Interpretation of the Comparisons with Statistics

The global gene expression profile in wildtype and PAI-1 knockout hearts and kidneys were compared. Four comparisons were made within four groups: Wildtype heart (WT/HT),
Knockout Heart (KO/HT), Wildtype Kidney (WT/KID) and Knockout Kidney (KO/KID). We compared Group1 (WT/HT) with Group2 (KO/HT), Group3 (WT/KID) with Group4 (KO/KID), Group2 (KO/HT) with Group4 (KO/KID) and Group1 (WT/HT) with Group3 (WT/KID) respectively (Figure 3). For the comparison, the first condition in the group name before the “vs.” sign is upregulated when the fold change has a positive, and is down-regulated when the fold change has a negative sign. The results of the probe-level differential gene expression were visualized by a volcano plot. While only a few genes were found to be differentially expressed between WT/HT and KO/HT (Figure 3A) and between WT/KID and KO/KID (Figure 3B), the expression patterns of numerous genes were significantly different when compared between KO/HT and KO/KID (Figure 3C) or between WT/HT and WT/KID (Figure 3D) as visualized by volcano plots.

Differentially Expressed Genes

Global gene expression profiling revealed that only 17 genes were differentially expressed in wildtype and PAI-1 knockout hearts. Out of 17 genes, 7 genes including Ankrd1, Dbp, Fbln2, P16 and Phlda 1 were upregulated and 10 genes including Acta2, H2-Ab1, Spon2 and Ces1d were downregulated in PAI-1 knockout hearts compared to age- and sex-matched wildtype controls (Table 1; see Table S1). Gene expression profiling revealed that 31 genes were differentially expressed in kidneys derived from PAI-1 knockout mice and wildtype mice. Out of 31 differentially expressed genes, 7 genes were upregulated including Pmr, Acea10, Aklba1 and 24 genes were downregulated including ler3, Erg1, Bcl6 and Dbp in PAI-1 knockout kidneys compared to age- and sex-matched control kidneys (Table 2; for details see Table S2). Almost 3900 genes were differentially expressed when compared between knockout hearts and knockout kidneys (Table S3). Many of these differentially expressed genes in knockout hearts and kidneys represent tissue-specific differential gene expression as well as differential expression influenced by PAI-1 deficiency as evidenced by altered fold change of expression of a particular gene when compared between WT/HT vs. WT/KID with KO/HT vs. KO/KID. While gene expression profiling was compared between wildtype hearts and kidneys, 4049 genes were differentially expressed (Table S4). These differentially expressed genes in wildtype hearts and kidneys represent only tissue-specific differential gene expression. This is one of the limitations of comparing of global gene expression profiling using two different tissues. However to overcome this issue, we further identified unique genes which are differentially expressed either only in the knockout heart and kidney comparison or in the wildtype heart and kidney comparison. Results revealed that while the expression of 223 genes out of 3900 differentially expressed common genes were altered uniquely in knockout heart and kidney (Table 3, Table S5, Figure 3E), 367 genes out of 4049 differentially expressed common genes showed altered expression uniquely in wildtype heart and kidney. For example, Agrp 1a, Vegfc, Sirt2, Rbl1 were upregulated and Ctgf, ler3, Junb were downregulated in wildtype heart compared to wildtype kidney (Table 4, Table S6; Figure 3E). Please note that the genes listed in Table 3 and Table 4 were unique in two comparisons. As the primary goal of the present study was to identify the differentially expressed genes related to matrix remodeling, we further analyzed the results of unique gene expression profiling in knockout hearts and kidneys (absent in wildtype heart and kidney comparison). We have identified several upregulated genes including Timp1, Dbp, Sxc, MMP23, Erg1, Enf2, Kl6 and Lox11 (Table 3A) in knockout hearts compared to knockout kidneys which may individually or together play an important role in matrix remodeling and cardiac fibrosis. The downregulated genes in knockout hearts compared to knockout kidneys include Xbp1, Stx7, Dad1, Cdk8 and Map3k11 (Table 3B).

Knockout Heart (KO/HT), Wildtype Kidney (WT/KID) and Knockout Kidney (KO/KID). We compared Group1 (WT/HT) with Group2 (KO/HT), Group3 (WT/KID) with Group4 (KO/KID), Group2 (KO/HT) with Group4 (KO/KID) and Group1 (WT/HT) with Group3 (WT/KID) respectively (Figure 3). For the comparison, the first condition in the group name before the “vs.” sign is upregulated when the fold change has a positive, and is down-regulated when the fold change has a negative sign. The results of the probe-level differential gene expression were visualized by a volcano plot. While only a few genes were found to be differentially expressed between WT/HT and KO/HT (Figure 3A) and between WT/KID and KO/KID (Figure 3B), the expression patterns of numerous genes were significantly different when compared between KO/HT and KO/KID (Figure 3C) or between WT/HT and WT/KID (Figure 3D) as visualized by volcano plots.

Differentially Expressed Genes

Global gene expression profiling revealed that only 17 genes were differentially expressed in wildtype and PAI-1 knockout hearts. Out of 17 genes, 7 genes including Ankrd1, Dbp, Fbln2, P16 and Phlda 1 were upregulated and 10 genes including Acta2, H2-Ab1, Spon2 and Ces1d were downregulated in PAI-1 knockout hearts compared to age- and sex-matched wildtype controls (Table 1; see Table S1). Gene expression profiling revealed that 31 genes were differentially expressed in kidneys derived from PAI-1 knockout mice and wildtype mice. Out of 31 differentially expressed genes, 7 genes were upregulated including Pmr, Acea10, Aklba1 and 24 genes were downregulated including ler3, Erg1, Bcl6 and Dbp in PAI-1 knockout kidneys compared to age- and sex-matched control kidneys (Table 2; for details see Table S2). Almost 3900 genes were differentially expressed when compared between knockout hearts and knockout kidneys (Table S3). Many of these differentially expressed genes in knockout hearts and kidneys represent tissue-specific differential gene expression as well as differential expression influenced by PAI-1 deficiency as evidenced by altered fold change of expression of a particular gene when compared between WT/HT vs. WT/KID with KO/HT vs. KO/KID. While gene expression profiling was compared between wildtype hearts and kidneys, 4049 genes were differentially expressed (Table S4). These differentially expressed genes in wildtype hearts and kidneys represent only tissue-specific differential gene expression. This is one of the limitations of comparing of global gene expression profiling using two different tissues. However to overcome this issue, we further identified unique genes which are differentially expressed either only in the knockout heart and kidney comparison or in the wildtype heart and kidney comparison. Results revealed that while the expression of 223 genes out of 3900 differentially expressed common genes were altered uniquely in knockout heart and kidney (Table 3, Table S5, Figure 3E), 367 genes out of 4049 differentially expressed common genes showed altered expression uniquely in wildtype heart and kidney. For example, Agrp 1a, Vegfc, Sirt2, Rbl1 were upregulated and Ctgf, ler3, Junb were downregulated in wildtype heart compared to wildtype kidney (Table 4, Table S6; Figure 3E). Please note that the genes listed in Table 3 and Table 4 were unique in two comparisons. As the primary goal of the present study was to identify the differentially expressed genes related to matrix remodeling, we further analyzed the results of unique gene expression profiling in knockout hearts and kidneys (absent in wildtype heart and kidney comparison). We have identified several upregulated genes including Timp1, Dbp, Sxc, MMP23, Erg1, Enf2, Kl6 and Lox11 (Table 3A) in knockout hearts compared to knockout kidneys which may individually or together play an important role in matrix remodeling and cardiac fibrosis. The downregulated genes in knockout hearts compared to knockout kidneys include Xbp1, Stx7, Dad1, Cdk8 and Map3k11 (Table 3B).
Biological Processes Representing Genes that were Differentially Expressed in Wildtype and PAI-1 Knockout Hearts

Genes involved in a wide variety of biological processes were deregulated in aged PAI-1 knockout hearts compared to age- and sex-matched wildtype controls. The biological processes depicting genes that were deregulated by the absence of PAI-1 are shown in Table 5 and Figure 4A. For examples: Ankrd1 which is involved in signal transduction, transcriptional regulation, and wound healing biological processes was upregulated in PAI-1 knockout hearts compared to wildtype hearts. Pi16 gene which is involved in the regulation of peptidase activity biological process and cardiac hypertrophy was also upregulated in PAI-1 knockout hearts compared to wildtype controls. H2-Ab1 and Spon2 genes, which are involved in immune response, were deregulated.

Biological Processes Representing Genes that were Differentially Expressed in Wildtype and PAI-1 Knockout Kidneys

Genes involved in different biological processes were also deregulated in PAI-1 knockout kidneys compared to age- and sex-matched wildtype controls. The biological processes depicting genes that were deregulated in kidneys due to PAI-1 deficiency are shown in Table 6 and Figure 4B. For examples: The genes Hbb-b1, Hba-a1, JunB, Egr1 and Bcl6 involved in immune system...
process and matrix remodeling were deregulated. The expression levels of genes involved in cell death, cell adhesion, proliferation, response to stress and wound healing biological processes were altered in the absence of PAI-1 suggesting these biological processes in kidneys are controlled directly or indirectly by PAI-1.

Biological Processes Representing Genes that were Differentially Expressed in PAI-1 Knockout Hearts and Kidneys

Numerous genes involved in a variety of biological processes were deregulated in aged PAI-1 knockout murine hearts when compared to the gene expression profile of PAI-1 knockout murine kidneys. Numerous genes involved in metabolism, cell proliferation, cell migration, cell adhesion, cell cycle, apoptosis, response to stress and wound healing were deregulated (Figure 4C and data not shown). We further analyzed the biological processes for the genes which are uniquely expressed only in the WT/HT vs. WT/KID comparison but not in the KO/HT vs. KO/KID comparison are shown in Table 7 and Figure 4D. Many of these deregulated genes are involved in transcriptional regulation, cellular differentiation and matrix organization including TIMP1, Scx, COL3A1, MMP23, IGFBP6, Klf6, Notch4, Timp2, Egr1, Dbp, Loxl1 and Il6st.

Biological Processes Representing Genes that were Differentially Expressed in Wildtype Hearts and Kidneys

The biological processes representing numerous genes were also differentially expressed (upregulated and downregulated) in wild-

| Table 2. Differential gene expression in wildtype and PAI-1 knockout kidneys. |
|------------------------|------------------------|--------|
| Gene Name Upregulated (A) | p value |
| Aldh1a1 | Aldehyde dehydrogenase 8 family, member A1 | 0.02 |
| Prlr | Prolactin receptor | 0.00002 |
| Hbb-b1 | Hemoglobin beta, adult major chain | 0.001 |
| Hbb-a1 | Hemoglobin alpha, adult chain 1 | 0.03 |
| Acad10 | Acyl-coenzyme dehydrogenase family, member 10 | 0.001 |
| Dnase1 | Deoxyribonuclease 1 | 0.009 |

| Gene Name Downregulated (B) | p value |
| Dusp1 | Dual specificity phosphatase 1 | 0.002 |
| Ier3 | Immediate early response 3 | 0.003 |
| Zfp36 | Zinc finger protein 36 | 0.001 |
| Zfp68 | Zinc finger protein 68 | 0.000002 |
| Junb | Junb oncogene | 0.007 |
| Prf1 | Perforin/serine protease | 0.04 |
| Egr1 | Early growth response 1 | 0.001 |
| Bcl6 | B cell lymphoma 6 | 0.02 |
| Dbp | D site albumin promoter binding protein | 0.02 |
| Mvp | Major vault protein | 0.005 |
| Chka | Choline kinase alpha | 0.009 |

| Table 3. Differential gene expression in PAI-1 knockout hearts and kidneys. |
|------------------------|------------------------|--------|
| Gene Name Upregulated (A) | p value |
| TIMP1 | Tissue inhibitor of metalloproteinase 1 | 0.02 |
| Dbp | D site albumin promoter binding protein | 0.01 |
| Scx | Scleraxis | 0.001 |
| Col3A1 | Collagen, type III, alpha 1 | 0.007 |
| MMP23 | Matrix metalloproteinase 23 | 0.01 |
| Igfbp6 | Insulin-like growth factor binding protein 6 | 0.005 |
| Klf6 | Kruppel-like factor 6 | 0.00005 |
| Notch4 | Notch gene homolog 4 | 0.0003 |
| Ebf2 | Early B cell factor 2 | 0.00005 |
| Timp2 | Tissue inhibitor of metalloproteinase 2 | 0.008 |
| Egr1 | Early growth response 1 | 0.0002 |
| Dusp1 | Dual specificity phosphatase 1 | 0.00001 |
| Loxl1 | Lysyl oxidase-like 1 | 0.02 |
| Il6st | Interleukin 6 signal transducer | 0.0002 |

| Gene Name Downregulated (B) | p value |
| Xbp1 | X-box binding protein 1 | 0.0005 |
| Stx7 | Syntaxin 7 | 0.003 |
| Map3k11 | Mitogen activated protein kinase kinase kinase 11 | 0.0001 |
| Zfp523 | Zinc finger protein 523 | 0.00001 |
| Dad1 | Defender against cell death 1 | 0.0001 |
| Cdk8 | Cyclin-dependent kinase 8 | 0.00004 |

Validation of Five Differentially Expressed Genes by qPCR

The expression levels of five differentially expressed genes related to wound healing, hypertrophy and matrix remodeling were validated by qPCR. These are Ankrd1, Prf1, Egr1, Dbp and Timp-1 (Figure 5A–E). Ankrd1 is an ankyrin repeat domain containing a transcription modulator and is involved in wound healing [25,26]. Quantitation of Ankrd1 mRNA by qPCR in wildtype and PAI-1 knockout heart and kidney samples revealed that while the level of Ankrd1 was significantly elevated in PAI-1 knockout hearts compared to wildtype controls (upregulated 4.88-fold; p = 0.005), the level of Ankrd1 mRNA was significantly decreased in PAI-1 knockout kidneys compared to wildtype heart and kidney. This result was expected as numerous genes involved in metabolism, stress response and proliferation biological processes were differentially expressed in hearts and kidneys simply due to cell-type and tissue-specific expression (Figure 4E and data not shown). We further analyzed the biological processes for the genes which are uniquely expressed only in the WT/HT vs. WT/KID comparison but not in the KO/HT vs. KO/KID comparison are shown in Table 8 and Figure 4F. Results showed that differentially expressed genes are involved in several biological processes including metabolic process, apoptosis, cell cycle, proliferation, migration, differentiation, immune system processes and response to stress. However, the majority of the differentially expressed genes in the WT/HT vs. WT/KID comparison represent tissue specific metabolic processes.

PLOS ONE | www.plosone.org | May 2013 | Volume 8 | Issue 5 | e63825
Effect of TGF-β on Ankrd1, Pi16, Timp1 and Timp4 Expression in Mouse Cardiac Endothelial Cells

As i) PAI-1 deficient mouse cardiac endothelial cells are more susceptible to EndMT [8], ii) EndMT-derived fibroblast-like cells synthesize excessive collagen and other profibrogenic factors compared to control cells [5,8,18], iii) the number of FSP-1 positive cells are significantly higher in PAI-1 knockout myocardial tissues [8], and iv) EndMT derived fibroblast-like cells in adult myocardium contributes to fibrogenesis (reviewed in [5] and references therein) here, we measured the protein levels of a few differentially expressed genes during EndMT. Equal amounts of protein from control mouse cardiac endothelial cells and TGF-β-induced EndMT-derived cells were subjected to Western blot analysis using specific antibodies against Ankrd1, Pi16, Timp1 and Timp4. Western blot results revealed that while the levels of Pi16, Ankrd1 and Timp1 proteins were elevated in response to TGF-β signaling, the level of Timp4 was decreased (Figure 6).

Discussion

Organ fibrosis is one of the major causes of organ failure-related deaths among the millions of patients with heart failure, renal failure, idiopathic pulmonary fibrosis, liver cirrhosis and systemic sclerosis [2,34–42]. Currently, there is no effective therapy for fibrosis. Although numerous studies have described the roles of different cytokines, transcriptional regulators and modulators involved in the processes of fibrogenesis [5,6,43], the major contributor in the initiation of fibrogenesis is uncertain. As TGF-β is the major architect of fibrogenic pathway activation, it was initially thought that antibody-mediated suppression of TGF-β activity would be an ideal approach to block fibrogenesis. However, blocking of TGF-β activity would be deleterious because TGF-β also controls other important biological processes including immunity, cellular proliferation and migration [37,44]. Therefore, there is an urgency to identify the igniters of fibrogenesis in order to develop a novel therapeutic approach to treat fibrosis. Previous studies demonstrated that aged plasminogen activator inhibitor-1 (PAI-1) knockout mice develop cardiac-selective fibrosis without affecting any other organs [8–10]. Here, we asked whether profibrotic factors responsible for fibrogenesis are differentially expressed in PAI-1 knockout hearts compared to PAI-1 knockout kidneys.

In order to identify the contributor(s) of cardiac fibrosis, we examined global differential gene expression in hearts and kidneys derived from PAI-1-knockout mice and age-matched wildtype controls. The present study identified several deregulated genes in PAI-1 knockout hearts compared to wildtype hearts and knockout kidneys. Several of these deregulated genes including Ankrd1, Egr1, Pi16, Dbp and Timp1 are related to wound healing, hypertrophy and transcriptional regulation of fibrogenesis [23,27–32,45]. Most importantly, while the expression profile of many of these genes was upregulated in PAI-1 knockout hearts, the
expression level of those genes was either unaffected or downregulated in PAI-1 knockout kidneys. These results indicate that these differentially expressed genes may contribute to the initiation of cardiac fibrogenesis, and PAI-1 knockout kidneys may be protected from fibrogenesis due to downregulation of these profibrotic regulators. The biology of these identified differentially expressed genes is discussed below in the light of fibrogenesis.

The present study demonstrated that Ankrd1 (Ankyrin repeat domain 1) was upregulated in PAI-1 knockout hearts but not in PAI-1 knockout kidneys. Ankrd1, a 36 kDa nuclear and cytoplasmic protein, is involved in signal transduction, cytokine stimulus response and RNA Pol II mediated transcriptional regulation [45]. In response to stretch stimuli, Ankrd1 translocates to the nucleus and acts as a nuclear signaling protein upon interaction with transcription factors and thus controls their function. Ankrd1 plays
a significant role in both positive and negative transcriptional regulation of cardiac gene expression as a transcriptional cofactor [45]. It has been reported that there is a left-right asymmetric distribution of Ankrd1, with increased level of expression in the left ventricle compared to right ventricle in a diastolic heart failure model [46]. Present results also demonstrated elevated levels of Ankrd1 protein in TGF-β-induced EndMT-derived fibroblast-like cells. Thus, elevated levels of Ankrd1 in PAI-1 knockout hearts may have contributions in the onset of cardiac fibrogenesis.

The present study revealed that while the level of Egr1 was elevated in PAI-1 knockout hearts compared to wildtype hearts and PAI-1 knockout kidneys, the level of Egr1 was decreased in PAI-1 knockout kidneys compared to wildtype controls. Egr-1 (Early growth response gene-1), an 82 kDa zinc finger transcription factor, is a known inducer of collagen synthesis and may contribute in the pathogenesis of fibrosis [28–31]. Interestingly, overexpressed Ankrd1 induces Egr-1 protein, a potent profibrotic regulator, in vitro [47]. Therefore, it is reasonable to propose that the presence of excess Ankrd1 in aged PAI-1 knockout hearts may be one of the key igniters of fibrogenesis via activation of the potent profibrotic transcription factor, Egr1. In contrast, PAI-1 knockout kidneys are protected from the onset of fibrogenesis due to lack of Ankrd1-Egr1 profibrogenic axis.

The expression level of Pi16 (peptidase inhibitor 16), a 47 kDa peptidase inhibitor, was significantly elevated in PAI-1 knockout hearts. In contrast there was no alteration in Pi16 expression in PAI-1 knockout kidneys, indicating influence of PAI-1 deficiency on Pi16 expression is organ and tissue-specific. Pi16 is a known regulator of cardiac hypertrophy and is upregulated in hypertrophy and heart failure. Although, cardiomyocyte-specific Pi16 overexpressing transgenic mice showed normal cardiac function, the size of their hearts were smaller with hypertrophic cardiomyocytes [27] indicating that Pi16 may be anti-hypertrophic. At present, the exact role of elevated Pi16 in cardiac fibrogenesis is unknown. The present data also showed that the protein level of Pi16 was elevated during EndMT in response to TGF-β2, indicating Pi16 is a target of TGF-β signaling. Further characterization of Pi16 in profibrotic signaling and its contribution to collagen and other matrix protein synthesis in vitro is required.

DBP (albumin D-site binding protein), a 34 kDa PAR-bZIP transcription factor, was upregulated in PAI-1 knockout hearts and downregulated in knockout kidneys compared to wildtype controls. Dbp is known to bind to promoters of many genes and control the expression levels of those genes, such as E-box driven clock genes CYP2A4 and CYP2A5 [32]. DBP also

| Table 5. Biological Processes representing genes that were differentially expressed in knockout hearts compared to wildtype hearts (for level of expression of each gene see Table S1). |

| Gene Ontology ID | Biological Processes | Gene Symbols |
|------------------|----------------------|-------------|
| GO:0045087       | innate immune response | H2-Ab1, Spon2 |
| GO:0030330       | DNA damage response, signal transduction | Ankrd1 |
| GO:0034097       | response to cytokine stimulus | H2-Ab1, Ankrd1 |
| GO:0006366       | transcription from RNA polymerase II promoter | Taf6, Ankrd1, Dbp |
| GO:0010811       | positive regulation of cell-substrate adhesion | Fbln2 |
| GO:0008285       | negative regulation of cell proliferation | Taf6, H2-Ab1 |
| GO:0048522       | positive regulation of cellular processes | H2-Ab1, Ankrd1, Dbp, Fbln2, Phlda1 |
| GO:0052547       | regulation of peptidase activity | Pi16 |
| GO:0006732       | coenzyme metabolic process | Acot1, Cers1d |

doi:10.1371/journal.pone.0063825.t005

| Table 6. Biological Processes representing genes that were differentially expressed in knockout kidneys compared to wildtype kidneys (for level of expression of each gene see Table S2). |

| Gene ontology ID | Biological Processes | Gene Symbols |
|------------------|----------------------|-------------|
| GO:0002376       | immune system process | Hbb-b1, Hba-a1, Zfp36, Junb, Prf1, Egr1, Bcl6 |
| GO:0008219       | cell death | Dusp1, Ier3, Pff1, Dnase1, Egr1, Bcl6 |
| GO:0030154       | cell differentiation | Prf1, Hbb-b1, Hba-a1, Zfp36, Junb, Egr1,Bcl6 |
| GO:0030155       | regulation of cell adhesion | Prf1, Bcl6 |
| GO:0030890       | positive regulation of B cell proliferation | Bcl6 |
| GO:0006950       | response to stress | Hbb-b1, Ier3, Zfp36, Pff1, Bcl6 |
| GO:0048583       | regulation of response to stimulus | Dusp1, Hbb-b1, Ier3, Zfp36, Egr1, Bcl6 |
| GO:0009611       | response to wounding | Ier3, Zfp36, Bcl6 |
| GO:0006366       | transcription from RNA pol II promoter | Zfp36, Junb, Egr1, Bcl6, Dbp |
| GO:0043487       | regulation of RNA stability | Zfp36 |
| GO:0044238       | primary metabolic process | Aldha1, Dusp1, Rbbd2, Rpp23, Prf1, Hbb-b1, Ier3, Zfp36, Hsd11b2, Junb, Dnase1, Egr1, Bcl6, Chka, Dbp |

doi:10.1371/journal.pone.0063825.t006
human PPAR-
Klf6, a 31 kDa zinc finger transcription factor, regulates TGF-
fibrogenesis [50,51] indicating elevated IGFBP6 in PAI-1 knock-
and delays cellular senescence. IGFBP6 may be involved in liver
knockout hearts may contribute to cardiac fibrogenesis; ii) IGFBP6
fibrotic tissues [3,49]. Therefore, elevated levels of Scx in PAI-1
expression and plays a significant role in matrix remodeling and
transcription factor, is an important regulator of collagen gene
included Scx, IGFBP6, Klf6, Notch4, Egr1, Timp1, Timp2 and
fatty liver diseases. Klf6 is also involved in oxidative stress-induced
stellate cell activation, inflammation and increased collagen
synthesis [52–54]. Therefore, elevated level of Klf6 may play a
role in cardiac-specific fibrosis; iv) Notch4, a 230 kDa Notch
signaling receptor, is significantly elevated in heart failure and may
play a role in myocardial matrix remodeling [55], indicating
enriched level of Notch4 in PAI-1 knockout hearts may have a
positive role in cardiac fibrogenesis; v) Egr1, a target of TGF-ß-
induced ERK1/2 MAP kinase signaling, plays a significant role in
fibrogenesis [28–31]. The elevated level of Egr1 in PAI-1 knockout
hearts compared to PAI-1 knockout kidneys illustrates its role in
fibrogenesis as discussed earlier; vi) Timp1 and Timp 2
play a role in myocardial matrix remodeling and fibrosis. Importantly, the level of Scx is significantly elevated in fibrotic
issues [3,49]. Therefore, elevated levels of Scx in PAI-1 knockout
hearts may contribute to cardiac fibrogenesis; ii) IGFBP6 (Insulin like growth factor binding protein 6), a 29 kDa modulator of
IGF activity, induces cellular proliferation, suppresses apoptosis and
defays cellular senescence. IGFBP6 may be involved in liver
fibrogenesis [50,51] indicating elevated IGFBP6 in PAI-1 knockout
hearts may play a role in cardiac-selective fibrogenesis; iii)
Klf6, a 31 kDa zinc finger transcription factor, regulates TGF-ß
gene expression and is associated with fibrosis in non-alcoholic
smallest monocytogenic tumors. They were transplanted to normal
recipient mice. Immunohistochemical staining was performed to
verify the success of transplants, and all transplanted tumor
samples were positive for cytokeratins. The tumors were
histologically similar to the original tumors. The transplanted
tumors showed a rapid growth rate, and they were positive for the
expression of cytokeratins. The results confirmed the successful
transplantation of the xenografts. The xenografts were examined
histologically and were found to be similar to the original tumors.
The expression of cytokeratins was positive in all transplanted
tumor samples.
may be involved in matrix remodeling under pathological conditions and the level of MMP23 is significantly elevated in idiopathic pulmonary fibrosis (IPF) [58,59]. As the level of MMP23 was significantly elevated in PAI-1 knockout hearts compared to wildtype kidneys [58,59]. As the level of MMP23 is significantly elevated in PAI-1 knockout hearts that lead to fibrogenesis, downregulation of those profibrotic factors may protect it from fibrogenesis (Figure 7).

Other than pro- and antifibrotic genes, numerous genes whose products are involved in a wide variety of biological processes such as adhesion, proliferation, migration, inflammation, apoptosis and metabolism, were also differentially expressed in PAI-1 knockout hearts and kidneys. Therefore, we cannot rule out the possibility of involvement of these genes in the initiation of cardiac-specific fibrosis and in the prevention of renal fibrosis. The rationale behind this notion comes from the observations that fibrogenic pathways can be activated or attenuated by different metabolic end products [64]; activation or differentiation of myofibroblasts from fibroblasts, endothelial cells or epithelial cells depends on other biological processes of these cells such as adhesion, proliferation, migration, inflammation, apoptosis and senescence [65]. Taken together, the results of the present study on global gene expression profiling in PAI-1 knockout hearts and kidneys established a strong functional link of PAI-1 with other biological processes of these cells such as adhesion, proliferation, migration, inflammation, apoptosis and metabolism, and senescence [65]. Taken together, the results of the present study on global gene expression profiling in PAI-1 knockout hearts and kidneys established a strong functional link of PAI-1 with other biological processes of these cells such as adhesion, proliferation, migration, inflammation, apoptosis and senescence [65].

Although the primary goal of this study was the identification of possible profibrotic factors differentially expressed in PAI-1 knockout kidneys from fibrogenesis. Therefore, in contrast to upregulation of a subset of profibrotic factors and downregulation of antifibrotic factors in PAI-1 knockout hearts that lead to fibrogenesis, downregulation of those profibrotic factors and upregulation of antifibrotic factor in PAI-1 knockout kidneys may protect it from fibrogenesis (Figure 7).
hearts and kidneys now available (online supplemental data) to other researchers working in the field of plasminogen-plasmin/u-PA/PAI-1 biology and PAI-1-associated diseases [5]. While many differentially expressed genes in PAI-1 knockout hearts and kidneys are simply due to tissue-specific gene expression, several genes involved in a number of biological processes are influenced by PAI-1 deficiency. To avoid tissue-specific differential expression of genes in the heart vs. kidney comparison, we further filtered and identified the genes which are uniquely expressed only in the PAI-1 knockout heart vs. PAI-1 knockout kidney comparison, and not common in the wildtype heart and kidney comparison vs. PAI-1 knockout heart and kidney comparison. However, there are several limitations dealing with global gene expression profiling using myocardial and renal tissues. One such limitation is the use of total RNA extracted from tissues. When using a mixture of RNA from different cell types including endothelial cells, fibroblasts, epithelial cells and myocytes, it is impossible to predict the specific cell type that is contributing to the differential expression of a particular gene. A second limitation is that activities of numerous transcription factors or regulators, controlling different biological processes in response to stress or signals, are altered only at the posttranslational levels like phosphorylation, acetylation etc. Therefore, it is another hurdle to identify those altered regulators in PAI-1 knockout hearts or kidneys by global

![Figure 5. Validation of expression levels of mRNAs in aged PAI-1 knockout and wildtype hearts and kidneys by qPCR analysis.](image)

Total RNA from wildtype and PAI-1 knockout heart and kidney tissues were used for quantitation of A. Ankrd1; B. Pi16; C. Egr1; D. Dbp and E. Timp1 by qPCR analysis using gene specific primers. Data represents mean of triplicates ± SEM. P value of each sample was indicated in the Figure A–E. doi:10.1371/journal.pone.0063825.g005

![Figure 6. Levels of Ankrd1, Pi16, Timp4 and Timp1 in TGF-β-treated endothelial cells.](image)

Mouse cardiac endothelial cells were treated with TGF-β2 (10 ng/ml) for 7 days. At the end of incubation, control and EndMT-derived fibroblast-like cells were harvested and whole lysates were prepared. Equal amounts of proteins were subjected to Western blot using specific antibodies as indicated. doi:10.1371/journal.pone.0063825.g006
gene expression profiling. For example, the levels of phosphorylated Smad2/3 are significantly elevated in PAI-1 knockout hearts compared to wildtype hearts [8]. Despite these limitations, the differential expression profile of each gene presented in this study came from whole tissue, a natural environment where expression patterns of a particular gene by a specific cell-type may be influenced by secreted products of other cell types as described [66].

In summary, the present study on global gene expression profiling of PAI-1 knockout and wildtype hearts and kidneys helps us to formulate a possible and robust hypothesis defining a pathway involving Ankrd1-Egr1-ECM genes that may explain the molecular basis of cardiac-selective fibrosis and lack of renal fibrosis in aged PAI-1 knockout mice. Along with the Ankrd1-Egr1 axis, a subset of profibrotic genes including Scx, Timp1/2, IGFBP6, Klf6 and Loxl1 may contribute to cardiac fibrogenesis. These genes were uniquely upregulated in PAI-1 knockout hearts compared to PAI-1 knockout kidneys (Figure 7). Therefore, the present study has established a platform for the future study of organ-specific fibrosis, the identification of igniters of fibrogenesis and the design of novel therapeutic approaches that could prevent either the onset of post-injury fibrogenesis or progression of initiated fibrosis.

Supporting Information

Figure S1 Collagen deposition in aged wildtype and PAI-1 knockout lungs and livers is comparable. The levels of collagen accumulation in lungs and livers derived from 24 m old wildtype and PAI-1 knockout mice were determined by Masson’s trichrome staining. A,B. Livers from 24 m old wildtype mouse (A) and 24 m old PAI-1 knockout mouse (B). C,D. Lungs from 24 m old wildtype mouse (C) and 24 m old PAI-1 knockout mouse (D). Quantitative data on collagen deposition are presented in the text.

Table S1 Differential gene expression in wildtype and PAI-1 knockout hearts. Up and Down regulation. ([+] upregulated genes in KO hearts compared to WT hearts; (−) downregulated in KO hearts compared to WT hearts)

Table S2 Differential gene expression in wildtype and PAI-1 knockout Kidney. Up and Down regulation. ([+] upregulated genes in KO kidneys compared to WT kidneys; (−) downregulated in KO kidneys compared to WT kidneys)

Table S3 Differential gene expression in PAI-1 knockout hearts and kidneys. Up and Down regulation: Common. ([+] upregulated genes in KO hearts compared to KO kidneys; (−) downregulated in KO hearts compared to KO kidneys)

Table S4 Differential gene expression in wildtype hearts and kidneys. Up and Down regulation: Common. ([+] upregulated genes in WT hearts compared to WT kidneys; (−) downregulated in WT hearts compared to WT kidneys)

Table S5 Differential gene expression in PAI-1 knockout hearts and kidneys. Up and Down regulation: Unique. ([+] upregulated genes in KO hearts compared to KO kidneys; (−) downregulated in KO hearts compared to KO kidneys)

Table S6 Differential gene expression in wildtype hearts and kidneys. Up and Down regulation: Unique. ([+]
upregulated genes in WT hearts compared to WT kidneys; (−) downregulated in WT hearts compared to WT kidneys]

(XLS)

Acknowledgments

Authors thankfully acknowledge the contribution of Northwestern University Genomic Core Facility in this work.

References

1. Wynn TA (2007) Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117: 524–529.
2. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199–210.
3. Crotty MP (2012) Common threads in cardiac fibrosis, infarct scar formation, and wound healing. Fibrogenesis Tissue Repair 5: 19.
4. Hu B, Phan SH (2013) Myofibroblasts. Curr Opin Rheumatol 25: 71–77.
5. Ghosh AK, Vaughan DE (2012) PAI-1 in Tissue Fibrosis. J Cell Physiol 227: 495–507.
6. Ghosh AK, Vaughan DE (2012) Fibrosis: is it a coactivator disease? Front Biosci 4: 1556–1570.
7. Edery AA (2000) Molecular basis of renal fibrosis. Pediatr Nephrol 15: 290–301.
8. Ghosh AK, Bradham WS, Gleeves LA, De Tarcy B, Murphy SB, et al. (2010) Genomic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice: Involvement of constitutive TGF-ß signaling and endothelial-to-mesenchymal transition. Circulation 122: 1200–1209.
9. Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA (2004) PAI-1 regulates epithelial polarization and mesenchymal-to-epithelial transition in carcinomas. J Biol Chem 279: 15759–15766.
10. Ookawa T, Watanabe H, Ueda A, Furuse M, Nakatani Y, et al. (2004) Essential role of plasminogen activator inhibitor type 1 in collagen induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97: 232–237.
11. Zirlik A, Ernst S, Leugers A, Willecke F, Solbe BE, et al. (2009) Inhibition of fibrosis by plasminogen activator inhibitor type 1 expression in human adipocytes and preadipocytes. Thromb Haemost 101: 1069–1070.
12. Kishore P, Li W, Tonelli J, Lee DE, Koppaka S, et al. (2010) Adipocyte-derived factors potentiate nutrient-induced production of plasminogen activator inhibitor type 1 by macrophages. Sci Transl Med 2: 20ra15.
13. Heymans S, Lupu F, Terclavers S, Vaesvteinkel B, Herbert JM, et al. (2005) Loss or inhibition of p42 or MPP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 166: 15–23.
14. De Tarcy B, Smith LH, Vaughan DE (2005) Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 5: 149–154.
15. Etzian DT, McCoy RD, Zheng X, Fay WP, Shen T, et al. (1996) Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97: 232–237.
16. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM (2001) PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60: 303–312.
17. Shi Y, Reitmaier B, Regenbogen J, Slowey RM, Opalenik SR, et al. (2005) CARP, a cardiac ankyrin repeat protein, is up-regulated during wound healing and induces angiogenesis in experimental granulation tissue. Am J Pathol 166: 303–312.
18. Samaras SE, Chen B, Koch SR, Sawyer DB, Lim CC, et al. (2012) 26S proteasome regulation of Ankrd1/CARP in adult rat ventricular myocytes and human microvascular endothelial cells. Biochem Biophys Res Commun 425: 830–835.
19. Wynn TA, Engelhardt S (2007) A secretory trap screen in yeast identifies protease inhibitor 16 as a novel antihypertrophic protein secreted from the heart. Circulation 116: 1767–1775.
20. Nakamura H, Isaka Y, Tsujie M, Rupprecht HD, Akagi Y, et al. (2002) Introduction of DNA enzyme for Egr-1 into tubulointerstitial fibroblasts by electroporation reduced interstitial s-smooth muscle actin expression and fibrosis in unilateral ureteral obstruction (UUO) rats. Gene Ther 9: 495–502.
21. Lee CG, Cho SJ, Kang MJ, Chapoval SP, Lee JJ, et al. (2004) Early growth response gene 1-mediated apoptosis is essential for transforming growth factor-ß-induced pulmonary fibrosis. J Exp Med 200: 377–389.
22. Cho SJ, Kang MJ, Homer RJ, Kang HR, Zhang X, et al. (2006) Role of early growth response-1 (Egr-1) in interleukin-15-induced inflammation and remodeling. J Biol Chem 281: 8161–8168.
23. Chen SJ, Ning H, Ishida W, Sodin-Semri S, Takaoka S, et al. (2006) The early-immediately gene Egr-1 is induced by transforming growth factor-ß and mediates stimulation of collagen gene expression. J Biol Chem 281: 21103–21107.
24. SethuNarayanan SR (2011) Role of the DBP Gene in the Regulation of Cardiac and Cyclic Hapatopsia: A Case for Potential Linkages Int J Hum Genet 11: 135–147.
25. Li YY, McMaster CF, Feldman AM (2000) Interplay of matrix metalloproteases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46: 214–224.
26. Berk BC, Fujitawa K, Lelovsz S (2007) ECM remodeling in hypertensive heart disease. J Clin Invest 117: 568–575.
27. Varjasi, J., Abraham D (2007) Systemic sclerosis: A prototypic multisystem fibrotic disorder. J Clin Invest 117: 557–567.
28. Pohlers D, Berrelloehl J, Loffler I, Muller CK, Leipner C, et al. (2009) TGF-ß and fibrosis in different organs: molecular pathway imprints. Biochem Biophys Acta 1792: 746–756.
29. Ghosh AK (2010) TGF-ß signaling and its inhibition: implication in fibrosis. Curr Enz Inhib 6: 54–56.
30. Ellmers LJ (2010) The role of transforming growth factor-ß in cardiac fibrosis. Curr Enz Inhib 6: 78–96.
31. Leak A (2010) Sticking it to scleroderma: Potential therapies blocking elevated adhesive and contractile signaling. Curr Enz Inhib 6: 97–104.
32. Mastuzaki K (2010) Smad3-mediated signals showing similarities and differences between epithelial and mesenchymal cells in human chronic liver diseases. Curr Enz Inhib 6: 54–56.
33. Varga J, Abraham D (2007) Systemic sclerosis: A prototypic multisystem fibrotic disease. J Clin Invest 117: 557–567.
34. Pohlers D, Berrelloehl J, Loffler I, Muller CK, Leipner C, et al. (2009) TGF-ß and fibrosis in different organs: molecular pathway imprints. Biochem Biophys Acta 1792: 746–756.
35. Ghosh AK (2010) TGF-ß signaling and its inhibition: implication in fibrosis. Curr Enz Inhib 6: 78–96.
36. Takahashi S, Inoue I, Nakajima Y, Seo M, Nakano T, et al. (2010) A promoter of plasminogen activator inhibitor 1 causes cardiac fibrosis in mice. Circ Res 95: 637–644.
37. Ghosh AK (2010) TGF-ß signaling and its inhibition: implication in fibrosis. Curr Enz Inhib 6: 303–312.
38. Massaguet J (2012) TGF-ß signaling in context. Nat Rev Mol Cell Biol 13: 616–630.
39. Mikhailov AT, Torrado M (2008) The etiologic role of the ankyrin repeat domain 1 gene in heart development and disease. Int J Dev Biol 52: 811–821.
40. Torrado M, Nesperieva B, Bouzamayo Y, Centeno A, Lopez E, et al. (2006) Differential atrial versus ventricular ANKR1D1 gene expression is oppositely regulated at diastolic heart failure. FEBS Lett 588: 4102–4108.
41. Reompler K, Pipp F, Fernandez U, Ziegelhoeffer T, Schaper W, et al. (2003) Arteriogenesis is associated with an induction of the cardiac ankyrin repeat protein (carp). Cardiovasc Res 59: 574–581.
42. Takahashi S, Ioue I, Nakajima Y, Seo M, Nakano T, et al. (2010) A promoter in the novel exon of PPPARy directs the cardiac expression of PPARy. J Atheroscler Thromb 17: 73–83.
43. Kardasinski M, Thum T (2009) Cardiac fibroblasts on the fast track: scleraxis from Achilles' heel to antifibrotic therapy. J Mol Cell Cardiol 47: 174–176.
44. Zhang ZZ (2007) The expression and significance of IGBP2, IGBP3 induced TGF-b1 in Hepatic Sclletal Cell. Master’s thesis summary. www.dissertationtopic.net/14138312, Accessed 2013, April 4.
45. Mieczkowska I, Diener T, Li C, Bogowska-Wrzesinska A, Mueck C, et al. (2011) Insulin-like growth factor binding protein-6 delays replicative senescence of human fibroblasts. Mech Ageing Dev 132: 468–479.
46. Starkel P, Sempoux C, Leclecre J, Herin M, Deby C, et al. (2003) Oxidative stress, KLF6 and transforming growth factor-ß up-regulation differentiate non-
alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol 39: 538–546.

53. Miele L, Beale G, Patman G, Nobili V, Leathart J, et al. (2008) The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 135: 282–291.

54. Mgbemena V, Segovia J, Chang T, Bose S (2011) Kruppel-like factor 6 regulates transforming growth factor-β gene expression during human respiratory syncytial virus infection. Virol J 8: 409. doi: 10.1186/1743-422X-8-409, Aug. 17, 2011.

55. Oie E, Sandberg WJ, Ahmed MS, Yndestad A, Lærum OD, et al. (2010) Activation of Notch signaling in cardiomyocytes during post-infarction remodeling. Scand Cardiovasc J 44: 359–366.

56. Nie QH, Duan GK, Luo XD, Xie YM, Luo H, et al. (2004) Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis. World J Gastroenterol 10: 86–90.

57. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metallo-proteinases; structure, function and biochemistry. Circ Res 92: 827–839.

58. Velasco G, Pendas AM, Fueyo A, Knüpfer V, Murphy G, et al. (1999) Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J Biol Chem 274: 4570–4576.

59. Pardo A, Schman M (2012) Role of matrix metalloproteinases in idiopathic pulmonary fibrosis. Fibrogenesis Tissue Repair (suppl 1): S9.

60. Phua YL, Martel N, Pennisi DJ, Little MH, Wilkinson I (2012) Distinct sites of renal fibrosis in the Crim1 mutant mice arise from multiple cellular origins. J Pathol doi: 10.1002/path.4155. [Epub ahead of print]

61. Xiao Q, Ge G (2012) Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. Cancer Microenv. 5: 261–273.

62. Doi S, Zou Y, Togao O, Pastor JV, John GB, et al. (2011) Klotho inhibits transforming growth factor-ß1 (TGF-ß1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 286: 8655–8665.

63. Sugiyama H, Yoshida T, Shiokura S, Kohei J, Mitobe M et al. (2012) Reduced Klotho expression level in kidney aggravates renal interstitial fibrosis. J Am Soc Nephrol 23: 1264–1273.

64. Phan SH, McGarry BM, Loeffler KM, Kunkel SL (1987) Regulation of macrophage-derived fibroblast growth factor release by arachidonate metabolites. J Leukoc Biol 42: 106–13.

65. Singh M, Foster CR, Dalal S, Singh K (2010) Role of osteopontin in heart failure associated with aging. Heart Fail Rev 15: 487–494.

66. Stoker AW, Streefland CH, Martins-Green M, Bissell MJ (1990) Designer microenvironments for the analysis of cell and tissue function. Curr Opin Cell Biol 2: 694–674.